Xbiotech’s Advanced Colorectal Cancer Candidate Meets Primary Endpoint

XBiotech’s advanced colorectal cancer therapy Xilonix met primary endpoints of improvement in lean body mass and quality of life in a European Phase 3 trial.

Roughly 33 percent of patients on the study drug saw improvements compared to 19 percent on placebo. Patients with refractory, metastatic colorectal cancer who suffered from cancer-associated symptoms such as fatigue, pain, elevated inflammatory markers, weight loss and reduced physical ability at baseline participated in the study. The endpoints were quantified by X-ray imaging and assessed based on patient-reported outcomes.

A therapeutic antibody, the biologic works by blocking inflammation believed to support tumor growth.